Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street
This article was originally published in RPM Report
Executive Summary
There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?